- Home
- IP vs DGX Comparison
IP vs DGX Comparison
Compare IP & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IP
- DGX
- Stock Information
- Founded
- IP 1898
- DGX 1967
- Country
- IP United States
- DGX United States
- Employees
- IP N/A
- DGX N/A
- Industry
- IP Paper
- DGX Medical Specialities
- Sector
- IP Basic Materials
- DGX Health Care
- Exchange
- IP Nasdaq
- DGX Nasdaq
- Market Cap
- IP 24.6B
- DGX 20.5B
- IPO Year
- IP N/A
- DGX 1996
- Fundamental
- Price
- IP $46.66
- DGX $189.64
- Analyst Decision
- IP Buy
- DGX Buy
- Analyst Count
- IP 8
- DGX 15
- Target Price
- IP $55.29
- DGX $188.47
- AVG Volume (30 Days)
- IP 3.8M
- DGX 891.8K
- Earning Date
- IP 10-30-2025
- DGX 10-21-2025
- Dividend Yield
- IP 3.97%
- DGX 1.69%
- EPS Growth
- IP N/A
- DGX 12.66
- EPS
- IP N/A
- DGX 8.35
- Revenue
- IP $21,934,000,000.00
- DGX $10,522,000,000.00
- Revenue This Year
- IP $45.44
- DGX $11.13
- Revenue Next Year
- IP $4.10
- DGX $3.41
- P/E Ratio
- IP N/A
- DGX $22.71
- Revenue Growth
- IP 18.13
- DGX 12.58
- 52 Week Low
- IP $43.27
- DGX $146.91
- 52 Week High
- IP $60.36
- DGX $191.49
- Technical
- Relative Strength Index (RSI)
- IP 49.70
- DGX 63.19
- Support Level
- IP $46.19
- DGX $178.54
- Resistance Level
- IP $47.17
- DGX $184.48
- Average True Range (ATR)
- IP 1.14
- DGX 3.40
- MACD
- IP 0.15
- DGX 0.49
- Stochastic Oscillator
- IP 77.83
- DGX 86.84
About IP International Paper Company
International Paper manufactures packaging products and cellulose fibers. It accounts for roughly one-third of the North American corrugated packaging market. The company also has a substantial presence in Europe following its acquisition of DS Smith. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.